Breaking News, Collaborations & Alliances

Cellares, Cabaletta Bio Ink 10-Year Commercial Supply Pact for Investigational CAR-T Therapy

The agreement follows the treatment’s first patient dosing milestone, involving an autologous therapy manufactured on an automated platform.

Author Image

By: Patrick Lavery

Content Marketing Editor

Cellares and Cabaletta Bio have signed a 10-year commercial supply agreement for automated manufacture of rese-cel (resecabtagene autoleucel). Rese-cel is Cabaletta’s investigational chimeric antigen receptor T-cell (CAR-T) therapy for autoimmune diseases. In securing long-term manufacturing capacity and supply predictability, the two companies cited global patient demand for rese-cel. That demand follows the companies’ first dosing milestone: patients dosed with an autologous CAR-T therapy m...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters